Implantable Infusion Pumps for Pain or Spasticity - Medicare Advantage (Revised)
Act
by Jul 1, 2025
Effective date
Jul 1, 2025
Identified
Jun 24, 2026
Summary
Humana Medicare Advantage has revised their policy for implantable infusion pumps used for pain or spasticity management, establishing specific medical necessity criteria including temporary trial requirements and success metrics. The policy provides detailed coverage determination guidelines for both antispasmodic drugs for severe spasticity and drugs for severe intractable pain treatment.
Get alerts when payers change rules like this one
We check Humana and other payers every day and email you when a change matches your specialty and state.
01Billing team must update prior authorization requirements for implantable infusion pump procedures to include documented temporary trial results, baseline Ashworth scores of at least 3 for spasticity cases, and evidence of 6-week failed conservative treatment.
02Providers must document FDA-approved drug usage and absence of contraindications.
03Update encounter forms to capture required medical necessity criteria as claims may be denied without proper documentation.
Summaries are AI-assisted. Always confirm against the original payer notice.
What is PolicyChanges
One workspace for payer rules, prior auth, coding and compliance
Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.